Leerink Partners analyst Puneet Souda maintained a Buy rating on Bruker (NASDAQ:BRKR) Corp on Thursday, setting a price target of $100, which is approximately 9.82% above the present share price of $91.06.
Souda expects Bruker Corp to post earnings per share (EPS) of $0.38 for the third quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Bruker, with an average price target of $87.
The analysts price targets range from a high of $100 to a low of $75.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $570.8 million and a net profit of $89.3 million. The company's market cap is $13.75 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.2% and a 67.00% success rate.
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the Bruker Scientific Instruments (BSI), and Bruker Energy and Supercon Technologies ( BEST (NYSE:BEST)) segments. The BSI segment comprises of the Bruker BioSpin Group, the Bruker CALID Group, and the Bruker Nano Group. The BEST segment designs, manufactures, and distributes superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications. The company was founded by Gunther Laukien in 1961 and is headquartered in Billerica, MA.